Pharvaris N.V. (PHVS)
NASDAQ: PHVS · Real-Time Price · USD
33.55
-1.39 (-3.98%)
At close: Jul 20, 2026, 4:00 PM EDT
33.55
0.00 (0.00%)
After-hours: Jul 20, 2026, 5:06 PM EDT
Pharvaris Employees
Pharvaris had 134 employees as of March 31, 2026. The number of employees increased by 5 or 3.88% since the number was last reported on December 31, 2025.
Employees
134
Change
5
Growth
3.88%
Revenue / Employee
n/a
Profits / Employee
-$1,450,369
Market Cap
2.34B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 134 | 5 | 3.88% |
| Dec 31, 2025 | 129 | 21 | 19.44% |
| Dec 31, 2024 | 108 | 26 | 31.71% |
| Dec 31, 2023 | 82 | 17 | 26.15% |
| Dec 31, 2022 | 65 | 31 | 91.18% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Agios Pharmaceuticals | 540 |
| Vericel | 398 |
| Tarsus Pharmaceuticals | 370 |
| Nurix Therapeutics | 317 |
| Biohaven | 274 |
| Immunome | 206 |
| Mineralys Therapeutics | 76 |
| Nektar Therapeutics | 63 |
PHVS News
- 5 days ago - Pharvaris initiated with an Overweight at Wells Fargo - TheFly
- 14 days ago - Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks - GlobeNewsWire
- 25 days ago - Pharvaris price target raised to $46 from $41 at Morgan Stanley - TheFly
- 5 weeks ago - Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026 - GlobeNewsWire
- 5 weeks ago - Pharvaris Announces Annual General Meeting of Shareholders - GlobeNewsWire
- 6 weeks ago - Pharvaris management to meet with Oppenheimer - TheFly
- 7 weeks ago - Pharvaris management to meet with Oppenheimer - TheFly
- 7 weeks ago - Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026 - GlobeNewsWire